ASBPW
Aspire Biopharma Holdings, Inc.
Biotechnology
Market Cap$125K
5Y Perf.-67.7%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ASBPW vs ACB vs SNDL vs IIPR
Revenue, margins, valuation, and 5-year total return — side by side.
ACB
Aurora Cannabis Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$195M
5Y Perf.-33.1%
SNDL
SNDL Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$376M
5Y Perf.-10.9%
IIPR
Innovative Industrial Properties, Inc.
REIT - Industrial
Market Cap$1.62B
5Y Perf.-20.4%
ASBPW vs ACB vs SNDL vs IIPR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ASBPW | ACB | SNDL | IIPR |
|---|---|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | REIT - Industrial |
| Market Cap | $125K | $195M | $376M | $1.62B |
| Revenue (TTM) | $2K | $361M | $937M | $263M |
| Net Income (TTM) | $-32M | $41M | $-11M | $120M |
| Gross Margin | 45.5% | 62.7% | 27.2% | 60.3% |
| Operating Margin | -10314.0% | 13.3% | -0.8% | 46.7% |
| Forward P/E | — | 164.2x | — | 13.5x |
| Total Debt | $1M | $104M | $170M | $394M |
| Cash & Equiv. | $4K | $184M | $273M | $48M |
ASBPW vs ACB vs SNDL vs IIPR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ASBPW
ACB
SNDL
IIPR
| Stock | Feb 25 | May 26 | Return |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBPW) | 100 | 32.3 | -67.7% |
| Aurora Cannabis Inc. (ACB) | 100 | 66.9 | -33.1% |
| SNDL Inc. (SNDL) | 100 | 89.1 | -10.9% |
| Innovative Industri… (IIPR) | 100 | 79.6 | -20.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASBPW vs ACB vs SNDL vs IIPR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IIPR leads in 5 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Aurora Cannabis Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ASBPW
Aspire Biopharma Holdings, Inc.
The Specific-Use Pick
ASBPW plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
ACB
Aurora Cannabis Inc.
The Growth Play
ACB is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
- 27.0% revenue growth vs ASBPW's -25.4%
- 5.2% ROA vs ASBPW's -13.2%
Best for: growth exposure
SNDL
SNDL Inc.
The Defensive Pick
SNDL is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 1.18, Low D/E 15.4%, current ratio 4.88x
- Beta 1.18, current ratio 4.88x
Best for: sleep-well-at-night and defensive
IIPR
Innovative Industrial Properties, Inc.
The Real Estate Income Play
IIPR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 9 yrs, beta 0.92, yield 13.5%
- 436.4% 10Y total return vs ASBPW's -81.9%
- Lower P/E (13.5x vs 164.2x)
- 45.6% margin vs ASBPW's -16K%
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ACB | 27.0% revenue growth vs ASBPW's -25.4% |
| Value | IIPR | Lower P/E (13.5x vs 164.2x) |
| Quality / Margins | IIPR | 45.6% margin vs ASBPW's -16K% |
| Stability / Safety | IIPR | Beta 0.92 vs ASBPW's 3.15 |
| Dividends | IIPR | 13.5% yield; 9-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | IIPR | +20.3% vs ASBPW's -66.2% |
| Efficiency (ROA) | ACB | 5.2% ROA vs ASBPW's -13.2% |
ASBPW vs ACB vs SNDL vs IIPR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2022
Segment breakdown not available.
ASBPW vs ACB vs SNDL vs IIPR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIIPRLAGGINGACB
Who Leads Where
IIPR leads in 3 of 6 categories
SNDL leads 1 • ASBPW leads 0 • ACB leads 0 • 1 tied
Explore the data ↓ACBAurora Cannabis Inc.
0leads
ASBPWAspire Biopharma Hold…
0leads
SNDLSNDL Inc.
1leads
IIPRInnovative Industrial…
3leads
6 Total Categories
CATEGORYLEADERvs SNDLvs ASBPWMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IIPR3/6
Valuation MetricsMultiples, price ratios, and targets
SNDL3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
IIPR6/6
Risk & VolatilityBeta, volatility, and downside exposure
IIPR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IIPR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SNDL is the larger business by revenue, generating $937M annually — 482943.3x ASBPW's $1,941. IIPR is the more profitable business, keeping 45.6% of every revenue dollar as net income compared to ASBPW's -16351.8%. On growth, ACB holds the edge at +6.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ASBPWAspire Biopharma … | ACBAurora Cannabis I… | SNDLSNDL Inc. | IIPRInnovative Indust… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $1,941 | $361M | $937M | $263M |
| EBITDAEarnings before interest/tax | -$28M | $71M | $49M | $197M |
| Net IncomeAfter-tax profit | -$32M | $41M | -$11M | $120M |
| Free Cash FlowCash after capex | -$4M | -$31M | $53M | $144M |
| Gross MarginGross profit ÷ Revenue | +45.5% | +62.7% | +27.2% | +60.3% |
| Operating MarginEBIT ÷ Revenue | -10314.0% | +13.3% | -0.8% | +46.7% |
| Net MarginNet income ÷ Revenue | -16351.8% | +11.2% | -1.2% | +45.6% |
| FCF MarginFCF ÷ Revenue | -1811.5% | -8.7% | +5.6% | +54.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +6.8% | -4.4% | -3.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +46.0% | -94.5% | +32.8% | -1.0% |
IIPR leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
SNDL leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 14.4x trailing earnings, IIPR trades at a 91% valuation discount to ACB's 164.2x P/E. On an enterprise value basis, ACB's 6.7x EV/EBITDA is more attractive than IIPR's 9.9x.
| Metric | ASBPWAspire Biopharma … | ACBAurora Cannabis I… | SNDLSNDL Inc. | IIPRInnovative Indust… |
|---|---|---|---|---|
| Market CapShares × price | $125,312 | $195M | $376M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $1M | $136M | $301M | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | 164.21x | -32.97x | 14.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 13.49x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 3.85x |
| EV / EBITDAEnterprise value multiple | — | 6.73x | 7.91x | 9.91x |
| Price / SalesMarket cap ÷ Revenue | — | 0.77x | 0.54x | 6.08x |
| Price / BookPrice ÷ Book value/share | — | 0.43x | 0.46x | 0.87x |
| Price / FCFMarket cap ÷ FCF | — | — | 8.83x | 9.26x |
SNDL leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
Evenly matched — ACB and IIPR each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-1 for SNDL. SNDL carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to IIPR's 0.21x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs ASBPW's 3/9, reflecting strong financial health.
| Metric | ASBPWAspire Biopharma … | ACBAurora Cannabis I… | SNDLSNDL Inc. | IIPRInnovative Indust… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +7.2% | -1.0% | +6.4% |
| ROA (TTM)Return on assets | -13.2% | +5.2% | -0.8% | +5.1% |
| ROICReturn on invested capital | — | +0.7% | -0.3% | +4.3% |
| ROCEReturn on capital employed | — | +0.7% | -0.4% | +5.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 6 | 4 |
| Debt / EquityFinancial leverage | — | 0.17x | 0.15x | 0.21x |
| Net DebtTotal debt minus cash | $1M | -$80M | -$102M | $346M |
| Cash & Equiv.Liquid assets | $3,633 | $184M | $273M | $48M |
| Total DebtShort + long-term debt | $1M | $104M | $170M | $394M |
| Interest CoverageEBIT ÷ Interest expense | -10.51x | 6.27x | -1.16x | 6.67x |
Evenly matched — ACB and IIPR each lead in 3 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
IIPR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IIPR five years ago would be worth $4,999 today (with dividends reinvested), compared to $385 for ACB. Over the past 12 months, IIPR leads with a +20.3% total return vs ASBPW's -66.2%. The 3-year compound annual growth rate (CAGR) favors IIPR at 4.5% vs ASBPW's -43.4% — a key indicator of consistent wealth creation.
| Metric | ASBPWAspire Biopharma … | ACBAurora Cannabis I… | SNDLSNDL Inc. | IIPRInnovative Indust… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -18.3% | -21.0% | -16.7% | +18.3% |
| 1-Year ReturnPast 12 months | -66.2% | -25.3% | +11.5% | +20.3% |
| 3-Year ReturnCumulative with dividends | -81.9% | -47.2% | -16.2% | +14.1% |
| 5-Year ReturnCumulative with dividends | -81.9% | -96.1% | -81.1% | -50.0% |
| 10-Year ReturnCumulative with dividends | -81.9% | -92.0% | -98.3% | +436.4% |
| CAGR (3Y)Annualised 3-year return | -43.4% | -19.2% | -5.7% | +4.5% |
IIPR leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
IIPR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IIPR is the less volatile stock with a 0.92 beta — it tends to amplify market swings less than ASBPW's 3.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IIPR currently trades 92.2% from its 52-week high vs ASBPW's 16.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ASBPWAspire Biopharma … | ACBAurora Cannabis I… | SNDLSNDL Inc. | IIPRInnovative Indust… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.54x | 1.80x | 1.17x | 0.91x |
| 52-Week HighHighest price in past year | $0.09 | $6.67 | $2.89 | $61.40 |
| 52-Week LowLowest price in past year | $0.01 | $3.07 | $1.15 | $44.58 |
| % of 52W HighCurrent price vs 52-week peak | +16.9% | +51.4% | +50.2% | +92.2% |
| RSI (14)Momentum oscillator 0–100 | 52.4 | 52.2 | 49.7 | 59.3 |
| Avg Volume (50D)Average daily shares traded | 23K | 979K | 1.9M | 303K |
IIPR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ACB as "Hold", SNDL as "Hold", IIPR as "Hold". Consensus price targets imply 172.4% upside for SNDL (target: $4) vs 49.6% for IIPR (target: $85). IIPR is the only dividend payer here at 13.46% yield — a key consideration for income-focused portfolios.
| Metric | ASBPWAspire Biopharma … | ACBAurora Cannabis I… | SNDLSNDL Inc. | IIPRInnovative Indust… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | — | $5.92 | $3.95 | $84.67 |
| # AnalystsCovering analysts | — | 14 | 6 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +13.5% |
| Dividend StreakConsecutive years of raises | — | — | — | 9 |
| Dividend / ShareAnnual DPS | — | — | — | $7.62 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.0% | +1.2% |
Insufficient data to determine a leader in this category.
Key Takeaway
IIPR leads in 3 of 6 categories (Income & Cash Flow, Total Returns). SNDL leads in 1 (Valuation Metrics). 1 tied.
Best OverallInnovative Industrial Prope… (IIPR)Leads 3 of 6 categories
Loading custom metrics...
ASBPW vs ACB vs SNDL vs IIPR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ASBPW or ACB or SNDL or IIPR a better buy right now?
For growth investors, Aurora Cannabis Inc.
(ACB) is the stronger pick with 27. 0% revenue growth year-over-year, versus -13. 8% for Innovative Industrial Properties, Inc. (IIPR). Innovative Industrial Properties, Inc. (IIPR) offers the better valuation at 14. 4x trailing P/E (13. 5x forward), making it the more compelling value choice. Analysts rate Aurora Cannabis Inc. (ACB) a "Hold" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ASBPW or ACB or SNDL or IIPR?
On trailing P/E, Innovative Industrial Properties, Inc.
(IIPR) is the cheapest at 14. 4x versus Aurora Cannabis Inc. at 164. 2x.
03Which is the better long-term investment — ASBPW or ACB or SNDL or IIPR?
Over the past 5 years, Innovative Industrial Properties, Inc.
(IIPR) delivered a total return of -50. 0%, compared to -96. 1% for Aurora Cannabis Inc. (ACB). Over 10 years, the gap is even starker: IIPR returned +439. 9% versus SNDL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ASBPW or ACB or SNDL or IIPR?
By beta (market sensitivity over 5 years), Innovative Industrial Properties, Inc.
(IIPR) is the lower-risk stock at 0. 91β versus Aspire Biopharma Holdings, Inc. 's 3. 54β — meaning ASBPW is approximately 291% more volatile than IIPR relative to the S&P 500. On balance sheet safety, SNDL Inc. (SNDL) carries a lower debt/equity ratio of 15% versus 21% for Innovative Industrial Properties, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ASBPW or ACB or SNDL or IIPR?
By revenue growth (latest reported year), Aurora Cannabis Inc.
(ACB) is pulling ahead at 27. 0% versus -13. 8% for Innovative Industrial Properties, Inc. (IIPR). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -381. 5% for Aspire Biopharma Holdings, Inc.. Over a 3-year CAGR, ACB leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ASBPW or ACB or SNDL or IIPR?
Innovative Industrial Properties, Inc.
(IIPR) is the more profitable company, earning 43. 0% net margin versus -16351. 8% for Aspire Biopharma Holdings, Inc. — meaning it keeps 43. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IIPR leads at 46. 7% versus -10314. 0% for ASBPW. At the gross margin level — before operating expenses — IIPR leads at 88. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ASBPW or ACB or SNDL or IIPR more undervalued right now?
Analyst consensus price targets imply the most upside for SNDL: 172.
4% to $3. 95.
08Which pays a better dividend — ASBPW or ACB or SNDL or IIPR?
In this comparison, IIPR (13.
5% yield) pays a dividend. ASBPW, ACB, SNDL do not pay a meaningful dividend and should not be held primarily for income.
09Is ASBPW or ACB or SNDL or IIPR better for a retirement portfolio?
For long-horizon retirement investors, Innovative Industrial Properties, Inc.
(IIPR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91), 13. 5% yield, +439. 9% 10Y return). Aspire Biopharma Holdings, Inc. (ASBPW) carries a higher beta of 3. 54 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IIPR: +439. 9%, ASBPW: -76. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ASBPW and ACB and SNDL and IIPR?
These companies operate in different sectors (ASBPW (Healthcare) and ACB (Healthcare) and SNDL (Healthcare) and IIPR (Real Estate)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: ASBPW is a small-cap quality compounder stock; ACB is a small-cap high-growth stock; SNDL is a small-cap quality compounder stock; IIPR is a small-cap deep-value stock. IIPR pays a dividend while ASBPW, ACB, SNDL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.